ZymoGenetics Allies With Bayer To Blitz U.S. Hospital Market With rhThrombin

 
• By Pamela Taulbee

Bayer receives ex-U.S. rights to develop and market the recombinant thrombin therapy.

More from Archive

More from Pink Sheet